Published on the 10 February 2020
ETAP-Lab’s dermatology activity keeps growing: our first project with a US-based company
By entrusting development of its drug candidate to our expertise, a NASDAQ-listed North American company is following the lead of European and Asian businesses by choosing ETAP-Lab’s DNCB-induced atop…
Company
